Alumis (ALMS) Stock Price, News & Analysis

Company Overview

Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses.

Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus. The company is also advancing additional pipeline programs, including A-005, an investigational TYK2 inhibitor designed to reach the central nervous system.

Alumis was formerly known as Esker Therapeutics and is headquartered in the United States. Its development programs are intended to support the treatment of patients with immune dysfunction in multiple global markets, subject to clinical and regulatory success.

Key Stats

• Today's Range: $6.64 to $7.31
• 50-Day Range: $6.85 to $28.95
• 52-Week Range: $3.96 to $31.35
• Volume: 2.62 million shs
• Average Volume: 3.09 million shs
• Market Capitalization: $886.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.27
• Consensus Rating: Moderate Buy

Alumis Stock Analysis - MarketRank™

Alumis scored higher than 83% of companies evaluated by MarketBeat, and ranked 82nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alumis has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alumis has a consensus price target of $33.27, representing about 385.7% upside from its current price of $6.85.

Amount of Analyst Coverage

Alumis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alumis are expected to grow in the coming year, from ($2.95) to ($2.84) per share.

Price to Book Value per Share Ratio

Alumis has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.34% of the float of Alumis has been sold short.

Short Interest Ratio / Days to Cover

Alumis has a short interest ratio ("days to cover") of 0.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alumis has recently increased by 11.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alumis does not currently pay a dividend.

Dividend Growth

Alumis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.79

News Sentiment

Alumis has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Alumis this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for ALMS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

MarketBeat Follows

4 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $9,178,027.00 in company stock, which represents 1.0352% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alumis insiders have bought 592.71% more of their company's stock than they have sold. Specifically, they have bought $10,726,520.00 in company stock and sold $1,548,493.00 in company stock.

Percentage Held by Insiders

33.70% of the stock of Alumis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Alumis has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALMS
• Previous Symbol: NASDAQ:ALMS
• CIK: 1847367
• Web: www.alumis.com
• Phone: (650) 231-6625
• Fax: N/A
• Employees: 239
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Alumis: $33.27
• High Price Target: $46.00
• Low Price Target: $15.00
• Potential Upside/Downside: +385.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$243.32 million
• Net Margins: -5,933.46%
• Pretax Margin: -5,957.21%
• Return on Equity: -93.15%
• Return on Assets: -74.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.74
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: $24.05 million
• Price / Sales: 36.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.88 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 129,430,000
• Free Float: 85,815,000
• Market Cap: $886.60 million
• Optionable: N/A
• Beta: -0.38